Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study



Document title: Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study
Journal: Annals of hepatology
Database: PERIÓDICA
System number: 000417072
ISSN: 1665-2681
Authors: 1
1
1
1
2
3
3
Institutions: 1Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, México, Distrito Federal. México
2Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Guadalajara, Jalisco. México
3Instituto Mexicano del Seguro Social, Centro Médico Nacional La Raza, México, Distrito Federal. México
Year:
Season: May-Jun
Volumen: 11
Number: 3
Pages: 364-368
Country: México
Language: Inglés
Document type: Artículo
Approach: Analítico, descriptivo
English abstract Identifying liver fibrosis is important to evaluate the severity of liver damage and to establish a prognosis. Utility of non-invasive markers of liver fibrosis has been proved in adults but there are few reports in children. The aim of this study was to evaluate Fibrotest® score and APRI suitability to identify children with liver fibrosis. Material and methods. 68 children with chronic liver disease requiring liver biopsy were prospectively included from three 3rd-level pediatric hospitals. The same pathologist evaluated all liver biopsies; fibrosis degree was determined by METAVIR score. Serum samples were obtained to determine Fibrotest® and APRI. AUROC were used to determine cut-off and differentiate between advanced fibrosis (METAVIR F3, F4) and no fibrosis (F0). Results. 68 biopsies were evaluated; METAVIR > F3 was identified in 26 (38%). Non invasive liver fibrosis markers to differentiate between advanced and no fibrosis were: Fibrotest® AUROC = 0.90 (95% CI 0.77-1.00) (cut-off value 0.35) sensitivity 88.00% (95% CI 68-96) and specificity 80% (95% CI 29-98); and for APRI AUROC = 0.97 (95% CI 0.92-1.00) (cut-off value 0.82), sensitivity 88% (95% CI 68-96) and specificity = 100% (95% CI 46-100). Conclusion. These results suggest the utility of Fibrotest® and APRI to identify advanced fibrosis; they can be recommended to select patients for liver biopsy and during patient follow-up
Disciplines: Medicina
Keyword: Gastroenterología,
Diagnóstico,
Pediatría,
Enfermedad hepática crónica,
Fibrosis hepática,
Marcadores diagnósticos
Keyword: Gastroenterology,
Diagnosis,
Pediatrics,
Chronic liver disease,
Liver fibrosis,
Diagnostic markers
Full text: Texto completo (Ver PDF)